Yes, it can cause low K+ in patient those have significant megaloblastic anemia, otherwise transient fall is insignificant
[9] Using retatrutide outside of an approved, ethics-committee-reviewed clinical trial carries significant risks, as research-grade peptides are not subject to the same manufacturing standards, purity controls, or safety oversight as licensed medicines
Long-lasting Effects The effects of APIT can be more sustained than some other treatments, reducing the frequency of treatments needed for chronic conditions
The compound demonstrates exceptional target selectivity, with no inhibition of related methyltransferases (DNMT1, PRMT3, COMT) or NAD+ salvage enzymes (NAMPT, SIRT1) at concentrations up to 600 M
[DOI] [PubMed] [Google Scholar] 86.Kook P.H., Melliger R.H., Hersberger M